scholarly journals Long-Term Neuroprotective Effect of Postischemic Hypothermia in a Neonatal Rat Model of Severe Hypoxic Ischemic Encephalopathy: A Comparative Study on the Duration and Depth of Hypothermia

2010 ◽  
Vol 68 (4) ◽  
pp. 303-308 ◽  
Author(s):  
Byong Sop Lee ◽  
Chul-Woong Woo ◽  
Sang-Tae Kim ◽  
Ki-Soo Kim
2017 ◽  
Vol 1659 ◽  
pp. 81-87 ◽  
Author(s):  
Bulent Goren ◽  
Aysen Cakir ◽  
Busra Ocalan ◽  
Sema Serter Kocoglu ◽  
Tulin Alkan ◽  
...  

2020 ◽  
Vol 8 ◽  
Author(s):  
Bhavna Gupta ◽  
Mary G. Hornick ◽  
Seema Briyal ◽  
Ramona Donovan ◽  
Preetha Prazad ◽  
...  

2019 ◽  
Vol 28 (12) ◽  
pp. 1552-1559 ◽  
Author(s):  
Jianwei Xu ◽  
Zhanhui Feng ◽  
Xianyao Wang ◽  
Ying Xiong ◽  
Lan Wang ◽  
...  

In this study, we investigated how human umbilical cord mesenchymal stem cells exerted a neuroprotective effect via antiapoptotic mechanisms in a neonatal hypoxic-ischemic encephalopathy rat model. A total of 78 10-day old (P10) rats were used. After human umbilical cord mesenchymal stem cells were collected from human umbilical cords and amplified in culture, they were administered to rat subjects 1 h after induced hypoxic-ischemic encephalopathy treatment. The short-term (48 h) and long-term (28 day) outcomes were evaluated after human umbilical cord mesenchymal stem cells treatment using neurobehavioral function assessment. Triphenyltetrazolium chloride monohydrate staining was performed at 48 h. Beclin-2 and caspase-3 levels were evaluated with Western blot and real time polymerase chain reaction at 48 h. Human umbilical cord mesenchymal stem cells were collected and administrated to hypoxic-ischemic encephalopathy pups by intracerebroventricular injection. Hypoxic-ischemic encephalopathy typically induced significant delay in development and caused impairment in both cognitive and motor functions in rat subjects. Human umbilical cord mesenchymal stem cells were shown to ameliorate hypoxic-ischemic encephalopathy-induced damage and improve both cognitive and motor functions. Although hypoxic-ischemic encephalopathy induced significant expression of caspase-3 and Beclin-2, human umbilical cord mesenchymal stem cells decreased the expression of both of them. Human umbilical cord mesenchymal stem cells may serve as a potential treatment to ameliorate brain injury in hypoxic-ischemic encephalopathy patients.


2019 ◽  
Vol 129 (11) ◽  
pp. 1139-1144 ◽  
Author(s):  
Ibrahim Hirfanoglu ◽  
Canan Turkyilmaz ◽  
Zafer Turkyilmaz ◽  
Esra Onal ◽  
Figen Soylemezoglu ◽  
...  

2003 ◽  
Vol 25 (7) ◽  
pp. 494-498 ◽  
Author(s):  
Adem Aydin ◽  
Kursad Genc̨ ◽  
Mustafa Akhisaroglu ◽  
Kutsal Yorukoglu ◽  
Necati Gokmen ◽  
...  

2020 ◽  
Vol 21 (23) ◽  
pp. 9193
Author(s):  
Liam M. Koehn ◽  
Xiaodi Chen ◽  
Aric F. Logsdon ◽  
Yow-Pin Lim ◽  
Barbara S. Stonestreet

Perinatal hypoxia-ischemia (HI) is a major cause of brain injury and mortality in neonates. Hypoxic-ischemic encephalopathy (HIE) predisposes infants to long-term cognitive deficits that influence their quality of life and place a large burden on society. The only approved treatment to protect the brain after HI is therapeutic hypothermia, which has limited effectiveness, a narrow therapeutic time window, and is not considered safe for treatment of premature infants. Alternative or adjunctive therapies are needed to improve outcomes of full-term and premature infants after exposure to HI. Inter-alpha inhibitor proteins (IAIPs) are immunomodulatory molecules that are proposed to limit the progression of neonatal inflammatory conditions, such as sepsis. Inflammation exacerbates neonatal HIE and suggests that IAIPs could attenuate HI-related brain injury and improve cognitive outcomes associated with HIE. Recent studies have shown that intraperitoneal treatment with IAIPs can decrease neuronal and non-neuronal cell death, attenuate glial responses and leukocyte invasion, and provide long-term behavioral benefits in neonatal rat models of HI-related brain injury. The present review summarizes these findings and outlines the remaining experimental analyses necessary to determine the clinical applicability of this promising neuroprotective treatment for neonatal HI-related brain injury.


Sign in / Sign up

Export Citation Format

Share Document